The year in cardiology: acute coronary syndromes

Banning, Adrian; Crea, Filippo; Lüscher, Thomas F.

doi:10.24170/17-2-4141

Cited by 2 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The authors confirmed their findings in two validation cohorts. However, when age is incorporated in the algorithm in order to improve the specificity, adding other confounders such as chronic kidney disease, chronic heart failure and atrial fibrillation should also be considered [17]. Twerenbold et al evaluated the real-world performance of the 0 h/1 h algorithm and confirmed its excellent applicability [18].…”

Section: H/1 H Algorithmmentioning

confidence: 99%

Recent developments in diagnosis and risk stratification of non-ST-elevation acute coronary syndrome

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: H/1 H Algorithmmentioning

confidence: 99%

Recent developments in diagnosis and risk stratification of non-ST-elevation acute coronary syndrome

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Соответственно, при обсуждении значимости исследования ISAR-REACT 5 мнения разделились. Так, часть специалистов не сочла имеющиеся недостатки критическими и в целом признала практическую ценность его результатов [14][15][16], в то время как другие указывают на недостаточную убедительность полученных данных [17,18].…”

Section: прямое сопоставление прасугрела и тикагрелора при раннем инвunclassified

Regarding the choice of Р2У<sub>12</sub> platelet receptor blocker in the early invasive approach to acute coronary syndrome treatment in patients without indications for long-term anticoagulant use

Явелов

2020

Aterotromboz

View full text Add to dashboard Cite

In case of early invasive approach to the treatment of acute coronary syndrome in patients without indications forlong-term anticoagulants, double antithrombocytic therapy is recommended - a combination of acetylsalicylic acid with one of the blockers of P2Y12 platelet receptor (clopidogrel, prasugrel or ticagrelor). In this case, patients who do not have an excessively high risk of bleeding, there is evidence in favor of the choice of prasugrel or ticagrelor. Which of them is preferable in cases where in the first hours after hospitalization it is planned to perform coronary stenting is not fully clarified.The drawbacks of the randomized open PRAGUE-18 study do not allow us to judge the comparative effectiveness and safety of prasugrel and ticagrelor in primary percutaneous coronary intervention.ц The ISAR-REACT 5 study was relatively small and has its strengths as well as weaknesses. However, the European expert community considers the results to be sufficient to change the practical approaches to acute coronary syndrome treatment. Thus, according to the recommendations of the European Society of Cardiology for the treatment of acute coronary syndrome without stable ST segment elevations on ECG, which were updated in September 2020, prasugrel is proposed to be considered as a preferred treatment for ticagrelor in cases where the patient is directed to percutaneous coronary intervention (class IIa recommendation, degree of evidence B).

show abstract

The year in cardiology: acute coronary syndromes

Abstract: Volume 17 Number 2 patients with STEMI, and, indeed, is a prognostic marker in these patients (see below). This might be relevant because risk stratification and management are probably different for plaque fissure and erosion.

Cited by 2 publications

References 51 publications

Recent developments in diagnosis and risk stratification of non-ST-elevation acute coronary syndrome

Recent developments in diagnosis and risk stratification of non-ST-elevation acute coronary syndrome

Regarding the choice of Р2У<sub>12</sub> platelet receptor blocker in the early invasive approach to acute coronary syndrome treatment in patients without indications for long-term anticoagulant use

Contact Info

Product

Resources

About